Seminars in Oncology
Volume 36 , Pages S20-S26 , April 2009

Proteasome Inhibitors in Multiple Myeloma

  • Kenneth C. Anderson

      Affiliations

    • Corresponding Author InformationAddress correspondence to Kenneth C. Anderson, MD, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Mayer 557, 44 Binney St, Boston, MA 02115

References 

  1. Goldberg AL, St John AC. Intracellular protein degradation in mammalian and bacterial cells: Part 2. Annu Rev Biochem. 1976;45:747–803
  2. Etlinger JD, Goldberg AL. A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc Natl Acad Sci U S A. 1977;74:54–58
  3. Hershko A, Ciechanover A, Rose IA. Resolution of the ATP-dependent proteolytic system from reticulocytes: a component that interacts with ATP. Proc Natl Acad Sci U S A. 1979;76:3107–3110
  4. Ciechanover A, Finley D, Varshavsky A. Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85. Cell. 1984;37:57–66
  5. Hershko A, Ciechanover A. The ubiquitin pathway for the degradation of intracellular proteins. Prog Nucleic Acid Res Mol Biol. 1986;33:19–56301
  6. Hough R, Pratt G, Rechsteiner M. Ubiquitin-lysozyme conjugates (Identification and characterization of an ATP-dependent protease from rabbit reticulocyte lysates). J Biol Chem. 1986;261:2400–2408
  7. Hough R, Rechsteiner M. Ubiquitin-lysozyme conjugates (Purification and susceptibility to proteolysis). J Biol Chem. 1986;261:2391–2399
  8. Hough R, Pratt G, Rechsteiner M. Purification of two high molecular weight proteases from rabbit reticulocyte lysate. J Biol Chem. 1987;262:8303–8313
  9. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003;29(Suppl 1):3–9
  10. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity. 1995;2:493–506
  11. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994;78:773–785
  12. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, et al. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev. 1995;9:1586–1597
  13. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996;87:1104–1112
  14. Shishodia S, Gutierrez AM, Lotan R, Aggarwal BB. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Cancer Res. 2005;65:9555–9565
  15. Sung MH, Bagain L, Chen Z, Karpova T, Yang X, Silvin C, et al. Dynamic effect of bortezomib on nuclear factor-kappaB activity and gene expression in tumor cells. Mol Pharmacol. 2008;74:1215–1222
  16. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23:10–24
  17. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006;66:6675–6682
  18. Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003;22:8386–8393
  19. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519–4527
  20. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639–16647
  21. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99:4079–4086
  22. McMillin DW, Negri J, Hayden P, Weisberg E, Klippel S, Zurawska J, et al. Compartment-specific bioluminescence imaging (CD-BLI): A high-throughput approach to identify novel anti-myeloma therapies that overcome the protection of stromal cells. Haematologica. 2007;92:65;(abstr S11.5)
  23. Chauhan D, Hideshima T, Anderson KC. Targeting proteasomes as therapy in multiple myeloma. Adv Exp Med Biol. 2008;615:251–260
  24. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–2617
  25. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. Survival, duration of response, and time to progression with bortezomib in patients with relapsed multiple myeloma: an update with additional follow-up. Proceedings of the 9th Annual EHA Congress, Geneva, Switzerland, June 10-13 2004;abstract 304
  26. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165–172
  27. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498
  28. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110:3557–3560
  29. Peles S, Fisher NM, Gao F, Tomasson MH, Dipersio JF, Vij R. A prospective study of the effects of once weekly bortezomib on markers of bone metabolism in patients with multiple myeloma (MM). J Clin Oncol. 2006;24:433s;(abstr 7548)
  30. Heider U, Kaiser M, Muller C, Schulz C-O, Jakob C, Zavrski I, et al. Treatment of bortezomib increases osteoblast function in patients with multiple myeloma. Blood. 2005;106:965a;(abstr 3457)
  31. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005;131:71–73
  32. San Miguel JF, Schlag R, Khuageva N, Shpilberg O, Dimopoulos M, Kropff M, et al. MMY-3002: a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood. 2007;110:31a;(abstr 76)
  33. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607–618
  34. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell. 2005;8:407–419
  35. Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood. 2008;111:2765–2775
  36. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377–2380
  37. Harousseau JL, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al. Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone. J Clin Oncol. 2007;25:441s;(abstr 8002)
  38. Richardson PG, Chanan-Khan A, Lonial S, Krishman A, Carroll M, Cropp GF, et al. Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): confirmation of the recommended dose using a novel formulation. Blood. 2007;110:353a;(abstr 1165)
  39. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525–4530
  40. Anderson KC, Jagannath S, Jakubowiak A, Lonial S, Raje N, Schlossman R, et al. Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM). J Clin Oncol. 2008;26:465s;(abstr 8545)
  41. Richardson PG, Lonial S, Jakubowiak S, Jagannath S, Raje N, Avigan DGIM, et al. Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): a phase I/II study. J Clin Oncol. 2008;26:459s;(abstr 8520)
  42. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107:4053–4062
  43. Richardson P, Jakubowiak A, Wolf J, Allerton J, Zonder J, Lonial S, et al. Phase I/II report from a multicenter trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed/refractory multiple myeloma previously treated with bortezomib. Blood. 2007;110:354a;(abstr 1170)
  44. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108:3441–3449
  45. Hideshima T, Bradner JE, Chauhan D, Anderson KC. Intracellular protein degradation and its therapeutic implications. Clin Cancer Res. 2005;11:8530–8533
  46. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005;102:8567–8572
  47. Weber DM, Jagannath S, Mazumder A, Sobecks R, Schiller GJ, Gavino M, et al. A phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma. Blood. 2007;110:355a;(abstr 1172)
  48. Badros A, Philip S, Niesvizky R, Goloubeva O, Harris C, Zweibel J, et al. Phase I trial of suberoylanilide hydroxamic acid (SAHA) + bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts). Blood. 2007;110:354a;(abstr 1168)
  49. Prince M, Quach H, Neeson P, Keegan M, Copeman M, Peinert S, et al. Safety and efficacy of the combination of bortezomib with the deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma: preliminary results of a phase I trial. Blood. 2007;110:353a;(abstr 1167)
  50. Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008;111:1654–1664

 STATEMENT OF CONFLICT OF INTEREST: Dr Anderson is supported by funding from Cephalon Oncology.

PII: S0093-7754(09)00029-3

doi: 10.1053/j.seminoncol.2009.02.001

Seminars in Oncology
Volume 36 , Pages S20-S26 , April 2009

Article Tools

* Image Usage & Resolution